crsp stock forecast 2025 gov capital
Based on 15 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. Full forecast for 2025 CRISPR Therapeutics CRSP Monthly Stock Prediction for 2026 Full forecast for 2026 CRISPR Therapeutics information and performance CRISPR.
The 2021 Long Term Budget Outlook Congressional Budget Office
Gov Capital Investor Blog.
. On average analysts forecast that. On average analysts forecast that CRSPs EPS will be -923 for 2022 with the lowest EPS forecast at -999 and the highest EPS forecast at -810. Target prices for 2022 2023 2024.
Price target in 14 days. Drug-developer Vaxart VXRT 422 is expected to increase its annual sales from the 405 million reported in 2020 to a consensus estimate of 1047 billion by mid-decade. Technical analysis historical chart.
Stock Price Forecast According to 32 stock analysts the average 12-month stock price forecast for CRSP stock is 11131 which predicts an increase of 10503. Stock Price Forecast The 23 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 10000 with a high estimate of 22000 and a low estimate of 3700. Their CRSP share price forecasts range from 3700 to 22000.
CRISPR Therapeutics AG Stock Forecast CRSP stock price prediction. Name 14d Forecast 3m Forecast 6m. 6449 D 366 245.
Forecast and historical charts. Stock price predictions forecasts with 14 days 3 months 6 months 1 year and 5 years timeline. Gov Capital drafted a more positive Teladoc Health stock forecast ranging from 9002 to 12179 a share for December 2022.
The weighted average target price per CRISPR Therapeutics share in Mar 2025 is. Short-term and long-term forecasts for CRISPR Therapeutics shares. CRSP Stock Price Prediction.
CRISPR Therapeutics stock forecast for 2025 by month. The average price target is 10331 with a high. Target values for the price of one CRISPR Therapeutics share for Mar 2025.
CRISPR Therapeutics AG CRSP stock forecast for 2022 2027. Target levels support and resistance levels. 16 analysts have issued 12-month price objectives for CRISPR Therapeutics shares.
The service expected the TDOC stock could.
Crispr Therapeutics Waiting On Early Data In 2h 2020 But The Clinical Pipeline Shows Promise 113 Upside Nasdaq Crsp Seeking Alpha
Crispr On The Cutting Edge Of Gene Editing Technology Nasdaq
Crispr Stock Forecasting Key Developments Nasdaq Crsp Seeking Alpha
Crispr Therapeutics Ag Stock Is Estimated To Be Significantly Overvalued
Short Term Energy Outlook U S Energy Information Administration Eia
Path To Equity Policy Guide For Richmond Connects Richmond
Crispr Stock Forecasting Key Developments Nasdaq Crsp Seeking Alpha
The Fed 1 Asset Valuation
Poet Laureate Suzanne Bruce Fairfield Ca
Councilmember Alex Pedersen
2022 U S China Annual Economic Report Ucla Anderson School Of Management
U S Energy Information Administration Eia Independent Statistics And Analysis
S 1
Crsp 10k 20201231 Htm
Office Of Budget And Management Ohio Gov
Storage Futures Energy Analysis Nrel
Dcp
Solar Futures Study Department Of Energy
Crsp 10k 20201231 Htm